Achievement of dual low-density lipoprotein cholesterol and high-sensitivity c-reactive protein targets more frequent with the addition of Ezetimibe to Simvastatin and associated with better outcomes in IMPROVE-IT.

Circulation. 2015;132:1224-33

Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White JA, Tershakovec AM, Blazing MA, Braunwald E